Tridem Bioscience

Tridem Bioscience is a private, preclinical-stage biotech focused on autoimmune and inflammatory diseases through a vaccine-based platform. The company is developing a lead candidate, TD-B01, for rheumatoid arthritis and other indications, aiming to induce antigen-specific immune tolerance. While still in early research and development, Tridem's approach targets a significant unmet medical need in large chronic disease markets. Its success hinges on validating its platform and advancing its pipeline through clinical trials.

Proprietary vaccine platform designed to induce antigen-specific immune tolerance for autoimmune diseases, potentially involving novel antigen delivery systems to promote regulatory immune responses.

Tridem operates in a highly competitive space competing against large pharmaceutical companies with approved biologics and novel therapies in development. It also competes with other biotechs exploring tolerance induction via different mechanisms, such as peptide therapy, cell therapy, or alternative antigen delivery systems.